Immunological Characteristics of Hyperprogressive Disease in Patients with Non-small Cell Lung Cancer Treated with Anti-PD-1/PD-L1 Abs

相似書籍

• Immune-related adverse events are clustered into distinct subtypes by T-cell profiling before and early after anti-PD-1 treatment
  由: Kim, Kyung Hwan, et al.
  出版: (2020)
• Regulatory (FoxP3(+)) T cells and TGF-β predict the response to anti-PD-1 immunotherapy in patients with non-small cell lung cancer
  由: Koh, Jiae, et al.
  出版: (2020)
• MDSC subtypes and CD39 expression on CD8(+) T cells predict the efficacy of anti‐PD‐1 immunotherapy in patients with advanced NSCLC
  由: Koh, Jiae, et al.
  出版: (2020)
• Mutational status of TP53 defines the efficacy of Wee1 inhibitor AZD1775 in KRAS-mutant non-small cell lung cancer
  由: Ku, Bo Mi, et al.
  出版: (2017)
• The biomarkers of hyperprogressive disease in PD-1/PD-L1 blockage therapy
  由: Wang, Xueping, et al.
  出版: (2020)